Razoxane and Vindesine in Advanced Soft Tissue Sarcomas: Impact on Metastasis, Survival and Radiation Response

Background: The treatment options in advanced soft tissue sarcomas (STS) are limited. In a pilot study, an anti-metastatic and radiosensitizing treatment concept was explored. Patients and Methods: Twenty-one patients with unresectable and/or oligometastatic STS received the drugs razoxane and vinde...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2007-09, Vol.27 (5B), p.3609-3614
Main Authors: RHOMBERG, Walter, EITER, Helmut, SCHMID, Franz, SAELY, Christoph
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Combined Modality Therapy
Dermatology
Female
Humans
Male
Medical sciences
Middle Aged
Neoplasm Metastasis
Prognosis
Razoxane - adverse effects
Razoxane - therapeutic use
Sarcoma - diagnosis
Sarcoma - drug therapy
Sarcoma - radiotherapy
Survival Analysis
Tumors
Tumors of the skin and soft tissue. Premalignant lesions
Vindesine - adverse effects
Vindesine - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: The treatment options in advanced soft tissue sarcomas (STS) are limited. In a pilot study, an anti-metastatic and radiosensitizing treatment concept was explored. Patients and Methods: Twenty-one patients with unresectable and/or oligometastatic STS received the drugs razoxane and vindesine supported by radiotherapy and surgery. Long-term treatment was intended in metastatic disease. Forty-one patients with comparable stages of STS treated with contemporary chemotherapy served as non-randomised controls. The prognostic parameters of the groups were comparable. Results: In the study group, the median number of new metastases after 6 months was 0 (range, 0-40) and after 9 months likewise 0 (0-70). The corresponding numbers in the control group were 4.5 (range, 0-40) and 9 (0->100) (p
ISSN:0250-7005
1791-7530